Increased gut microbial translocation in HIV-infected children persists in virologic responders and virologic failures after antiretroviral therapy - PubMed (original) (raw)
Increased gut microbial translocation in HIV-infected children persists in virologic responders and virologic failures after antiretroviral therapy
Sudheesh Pilakka-Kanthikeel et al. Pediatr Infect Dis J. 2012 Jun.
Abstract
Background: Gut microbial translocation (MT) is considered a major cause of immune activation (IA) and failure of immune reconstitution in HIV infection. This study investigated the relationship of virus replication, IA, CD4 counts and MT in HIV-infected children.
Methods: Lipopolysaccharide, bacterial 16S ribosomal DNA (16SrDNA) and soluble CD14 (sCD14) levels were determined in prospectively collected, stored plasma samples from the Pediatric AIDS Clinical Trials Group Protocol P338, a 48-week study initiated in 1997 to compare efficacy of dual nucleosides with a ritonavir-containing regimen. Results of MT were correlated with study data for T cell IA, plasma viral load and CD4 counts in 85 HIV-infected children (ages 2-17 years) designated as virologic responders or virologic failures (VF) at week 44 based on a cutoff of 400 HIV RNA copies/mL.
Results: Levels of plasma lipopolysaccharide, 16SrDNA and sCD14 were increased in comparison with HIV-uninfected controls and did not decrease at week 44 even in virologic responders. T cell IA was correlated with viral load and sCD14 at entry and with 16SrDNA and sCD14 at week 44 in total patients and in the VF group. Changes in 16SrDNA correlated with changes in IA and negatively with changes in CD4 counts. 16SrDNA was correlated with sCD14 but not with lipopolysaccharide.
Conclusions: MT persists after 44 weeks of antiretroviral therapy in VS and VF patients. In VF, 16SrDNA exhibited relationships to monocyte and T cell IA and CD4 counts but not with viral load, suggesting a dominant role for MT in disease pathogenesis in HIV-infected children.
Conflict of interest statement
Potential conflict of interest: none
Figures
Figure 1. Plasma levels of microbial products and sCD14 (indicating monocyte activation) are elevated in HIV infected children; LPS does not correlate with 16SrDNA
(A) Correlation between LPS and 16SrDNA; (B, C, D), plasma levels of LPS, 16SrDNA, and sCD14 respectively in total patients; (E), values of sCD14 in virologic responders (VR) and virologic failures (VF). Differences within groups were analyzed using Student’s paired 2-tailed t-test.
Figure 2. Correlation of microbial translocation products with sCD14
(A), Corrleation of LPS with sCD14 at baseline in total patients; (B, C); Correlation of 16SrDNA with sCD14 at week 0 and week 44 respectively in total patients; (D, E), Correlation of 16SrDNA with sCD14 at week 44 in VF and VR groups respectively. Spearman correlations (r and p values) were used to examine the relationships between the markers.
Figure 3. 16sRDNA correlates with T cell immune activation at week 44 in total patients and VF group, but not with VR group
16SrDNA copy number correlated with activated CD4 T cells; CD8 T cells respectively (A, B), in total patients; (C,D), Virologic failures; (E,F), Virologic responders. Spearman correlations (r and p values) were used to examine the relationships between 16SrDNA copy number and activation markers.
Figure 4. Monocyte activation (sCD14) correlates with T cell activation at Week 0 and Week 44 in total patients and in VF, but not in VR patients
Correlation of plasma sCD14 (A,B) with activated CD4 T cells at week 0 and 44 respectively in all patients; (C,D), with activated CD8 T cells at week 0 and 44 in all patients; (E,F), with activated CD4 T cells and activated CD8 T cells respectively at week 44 in VF; (G,H), with activated CD4 T cells and activated CD8 T cells respectively in VR at week 44. Spearman correlations (r and p values) were used to examine the relationships between sCD14 and immune activation markers (percentages of HLA-DR +CD38+) on CD4 and CD8 T cells.
Figure 5. T cell activation correlates with virus load at week 0 in total patients, not at week 44 in total patients or in VF
Virus load correlations with activated CD4 T cells and activated CD8 T cells respectively, (A, B), in total patients at week 0; (C, D), in total patients at week 44; and (E, F) in VF patients at week 44. Spearman correlations (r and p values) were used to examine the relationships between Log HIV RNA and immune activation markers (percentages of HLA-DR +CD38+) on CD4 and CD8 T cells.
Similar articles
- Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting.
Pilakka-Kanthikeel S, Kris A, Selvaraj A, Swaminathan S, Pahwa S. Pilakka-Kanthikeel S, et al. J Acquir Immune Defic Syndr. 2014 May 1;66(1):16-24. doi: 10.1097/QAI.0000000000000096. J Acquir Immune Defic Syndr. 2014. PMID: 24378729 Free PMC article. - Correlation between different methods to measure microbial translocation and its association with immune activation in long-term suppressed HIV-1-infected individuals.
Abad-Fernández M, Vallejo A, Hernández-Novoa B, Díaz L, Gutiérrez C, Madrid N, Muñoz MA, Moreno S. Abad-Fernández M, et al. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):149-53. doi: 10.1097/QAI.0b013e31829a2f12. J Acquir Immune Defic Syndr. 2013. PMID: 24047967 Clinical Trial. - Microbial Translocation and Immune Activation in HIV-1 Infected Pregnant Women.
Mitchell CD, Dominguez S, Roach M, George V, Rinaldi S, Fischl M, Potter J, Tyson B, Pahwa S. Mitchell CD, et al. Curr HIV Res. 2018;16(3):208-215. doi: 10.2174/1570162X16666180731145011. Curr HIV Res. 2018. PMID: 30062968 Free PMC article. - Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K. Van Vaerenbergh K. Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Verh K Acad Geneeskd Belg. 2001. PMID: 11813503 Review. - [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida. Panel de expertos de GESIDA y Plan Nacional sobre el Sida. Enferm Infecc Microbiol Clin. 2011 Mar;29(3):209.e1-103. doi: 10.1016/j.eimc.2010.12.004. Enferm Infecc Microbiol Clin. 2011. PMID: 21388714 Spanish.
Cited by
- Immunological age prediction in HIV-infected, ART-treated individuals.
de Armas LR, Pallikkuth S, Pan L, Rinaldi S, Pahwa R, Pahwa S. de Armas LR, et al. Aging (Albany NY). 2021 Oct 11;13(19):22772-22791. doi: 10.18632/aging.203625. Epub 2021 Oct 11. Aging (Albany NY). 2021. PMID: 34635604 Free PMC article. - Targeting Phosphodiesterases-Towards a Tailor-Made Approach in Multiple Sclerosis Treatment.
Schepers M, Tiane A, Paes D, Sanchez S, Rombaut B, Piccart E, Rutten BPF, Brône B, Hellings N, Prickaerts J, Vanmierlo T. Schepers M, et al. Front Immunol. 2019 Jul 24;10:1727. doi: 10.3389/fimmu.2019.01727. eCollection 2019. Front Immunol. 2019. PMID: 31396231 Free PMC article. Review. - Altered Intestinal Permeability and Fungal Translocation in Ugandan Children With Human Immunodeficiency Virus.
Dirajlal-Fargo S, El-Kamari V, Weiner L, Shan L, Sattar A, Kulkarni M, Funderburg N, Nazzinda R, Karungi C, Kityo C, Musiime V, McComsey GA. Dirajlal-Fargo S, et al. Clin Infect Dis. 2020 May 23;70(11):2413-2422. doi: 10.1093/cid/ciz561. Clin Infect Dis. 2020. PMID: 31260509 Free PMC article. - Following spinal cord injury, PDE4B drives an acute, local inflammatory response and a chronic, systemic response exacerbated by gut dysbiosis and endotoxemia.
Myers SA, Gobejishvili L, Saraswat Ohri S, Garrett Wilson C, Andres KR, Riegler AS, Donde H, Joshi-Barve S, Barve S, Whittemore SR. Myers SA, et al. Neurobiol Dis. 2019 Apr;124:353-363. doi: 10.1016/j.nbd.2018.12.008. Epub 2018 Dec 14. Neurobiol Dis. 2019. PMID: 30557659 Free PMC article. - High Abundance of genus Prevotella in the gut of perinatally HIV-infected children is associated with IP-10 levels despite therapy.
Kaur US, Shet A, Rajnala N, Gopalan BP, Moar P, D H, Singh BP, Chaturvedi R, Tandon R. Kaur US, et al. Sci Rep. 2018 Dec 5;8(1):17679. doi: 10.1038/s41598-018-35877-4. Sci Rep. 2018. PMID: 30518941 Free PMC article.
References
- Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83–92. - PubMed
- Lederman MM, Kalish LA, Asmuth D, Fiebig E, Mileno M, Busch MP. ‘Modeling’ relationships among HIV-1 replication, immune activation and CD4+ T-cell losses using adjusted correlative analyses. AIDS. 2000;14:951–958. - PubMed
- Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881–1888. - PubMed
- Deeks SG, Kitchen CM, Liu L, Guo H, Gascon R, Narvaez AB, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942–947. - PubMed
- Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–1371. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01 AI068632/AI/NIAID NIH HHS/United States
- UM1 AI068632/AI/NIAID NIH HHS/United States
- P30 AI073961/AI/NIAID NIH HHS/United States
- AI068632/AI/NIAID NIH HHS/United States
- U01AI068632/AI/NIAID NIH HHS/United States
- A1077501/PHS HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials